RG6221 / Roche - LARVOL DELTA

A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors. (clinicaltrials.gov) - P1 | N=180 | Not yet recruiting | Sponsor: Hoffmann-La Roche

Combination therapy • Metastases • New P1 trial • Oncology • Solid Tumor

Another phase 1 drug sunk by early data is FAP-LTBR, also known as RG6221, a LTBR agonist in development for solid tumors. (FierceBiotech) - "'The current dataset from the phase 1 trial suggests that continued enrollment is highly unlikely to generate results that justify further clinical development of the molecule.'....The final asset to be dumped today was another solid tumor drug called RG6561."

Discontinued • Solid Tumor

A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=34 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Recruiting ➔ Active, not recruiting | N=180 ➔ 34

Enrollment change • Enrollment closed • Oncology • Solid Tumor

FAP-LTBR (RO7567132): A first-in-class bi-specific stromal immunomodulatory agonist designed to enable and enhance efficacy of cancer immunotherapies (AACR 2025) - P1 | "Treatment with the murine surrogate of RO7567132 led to tumor growth inhibition in a breast cancer model and showed greater efficacy when combined with the murine surrogate of atezolizumab in both breast cancer and fibrosarcoma models. Additionally, in a slow-growing orthotopic mouse colorectal cancer model, treatment with the murine surrogate of RO7567132 increased the content of immune cells (T and B cells) and HEVs in tumors and induced the formation of immune cell niches resembling TLS.RO7567132 was well tolerated in both a 2-week non-GLP Maximum tolerated dose/Dose range-finding (MTD/DRF) study and a 4-week GLP toxicology study in cynomolgus monkeys at doses up to 10 mg/kg, with no associated adverse findings.RO7567132 is currently being tested in an open-label, multicenter, dose-escalation, randomized, phase1 study (NCT06537310) to evaluate safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of RO7567132, as a single agent and in combination..."

Clinical • Immunomodulating • IO biomarker • Stroma • Breast Cancer • Colorectal Cancer • Fibrosarcoma • Oncology • Sarcoma • Solid Tumor • CXCL13 • TNFA

A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors. (clinicaltrials.gov) - P1 | N=180 | Recruiting | Sponsor: Hoffmann-La Roche | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Metastases • Oncology • Solid Tumor